Extended treatment for cigarette smoking cessation: a randomized control trial

Jennifer R. Laude, Steffani Bailey, Erin Crew, Ann Varady, Anna Lembke, Danielle McFall, Anna Jeon, Diana Killen, Joel D. Killen, Sean P. David

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Aim: To test the potential benefit of extending cognitive–behavioral therapy (CBT) relative to not extending CBT on long-term abstinence from smoking. Design: Two-group parallel randomized controlled trial. Patients were randomized to receive non-extended CBT (n = 111) or extended CBT (n = 112) following a 26-week open-label treatment. Setting: Community clinic in the United States. Participants: A total of 219 smokers (mean age: 43 years; mean cigarettes/day: 18). Intervention: All participants received 10 weeks of combined CBT + bupropion sustained release (bupropion SR) + nicotine patch and were continued on CBT and either no medications if abstinent, continued bupropion + nicotine replacement therapy (NRT) if increased craving or depression scores, or varenicline if still smoking at 10 weeks. Half the participants were randomized at 26 weeks to extended CBT (E-CBT) to week 48 and half to non-extended CBT (no additional CBT sessions). Measurements: The primary outcome was expired CO-confirmed, 7-day point-prevalence (PP) at 52- and 104-week follow-up. Analyses were based on intention-to-treat. Findings: PP abstinence rates at the 52-week follow-up were comparable across non-extended CBT (40%) and E-CBT (39%) groups [odds ratio (OR) = 0.99; 95% confidence interval (CI) = 0.55, 1.78]. A similar pattern was observed across non-extended CBT (39%) and E-CBT (33%) groups at the 104-week follow-up (OR = 0.79; 95% CI= 0.44, 1.40). Conclusion: Prolonging cognitive–behavioral therapy from 26 to 48 weeks does not appear to improve long-term abstinence from smoking.

Original languageEnglish (US)
Pages (from-to)1451-1459
Number of pages9
JournalAddiction
Volume112
Issue number8
DOIs
StatePublished - Aug 1 2017

Fingerprint

Smoking Cessation
Smoking
Therapeutics
Bupropion
Odds Ratio
Confidence Intervals
Tobacco Use Cessation Products
Carbon Monoxide
Nicotine
Tobacco Products
Randomized Controlled Trials

Keywords

  • Abstinence
  • adaptive treatment
  • bupropion SR
  • clinical trial
  • cognitive behavioral therapy
  • extended treatment
  • nicotine dependence
  • nicotine replacement therapy smoking cessation
  • smoking cessation
  • varenicline

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Psychiatry and Mental health

Cite this

Laude, J. R., Bailey, S., Crew, E., Varady, A., Lembke, A., McFall, D., ... David, S. P. (2017). Extended treatment for cigarette smoking cessation: a randomized control trial. Addiction, 112(8), 1451-1459. https://doi.org/10.1111/add.13806

Extended treatment for cigarette smoking cessation : a randomized control trial. / Laude, Jennifer R.; Bailey, Steffani; Crew, Erin; Varady, Ann; Lembke, Anna; McFall, Danielle; Jeon, Anna; Killen, Diana; Killen, Joel D.; David, Sean P.

In: Addiction, Vol. 112, No. 8, 01.08.2017, p. 1451-1459.

Research output: Contribution to journalArticle

Laude, JR, Bailey, S, Crew, E, Varady, A, Lembke, A, McFall, D, Jeon, A, Killen, D, Killen, JD & David, SP 2017, 'Extended treatment for cigarette smoking cessation: a randomized control trial', Addiction, vol. 112, no. 8, pp. 1451-1459. https://doi.org/10.1111/add.13806
Laude JR, Bailey S, Crew E, Varady A, Lembke A, McFall D et al. Extended treatment for cigarette smoking cessation: a randomized control trial. Addiction. 2017 Aug 1;112(8):1451-1459. https://doi.org/10.1111/add.13806
Laude, Jennifer R. ; Bailey, Steffani ; Crew, Erin ; Varady, Ann ; Lembke, Anna ; McFall, Danielle ; Jeon, Anna ; Killen, Diana ; Killen, Joel D. ; David, Sean P. / Extended treatment for cigarette smoking cessation : a randomized control trial. In: Addiction. 2017 ; Vol. 112, No. 8. pp. 1451-1459.
@article{69bab562c0b44c8aa6a2248cf4134db2,
title = "Extended treatment for cigarette smoking cessation: a randomized control trial",
abstract = "Aim: To test the potential benefit of extending cognitive–behavioral therapy (CBT) relative to not extending CBT on long-term abstinence from smoking. Design: Two-group parallel randomized controlled trial. Patients were randomized to receive non-extended CBT (n = 111) or extended CBT (n = 112) following a 26-week open-label treatment. Setting: Community clinic in the United States. Participants: A total of 219 smokers (mean age: 43 years; mean cigarettes/day: 18). Intervention: All participants received 10 weeks of combined CBT + bupropion sustained release (bupropion SR) + nicotine patch and were continued on CBT and either no medications if abstinent, continued bupropion + nicotine replacement therapy (NRT) if increased craving or depression scores, or varenicline if still smoking at 10 weeks. Half the participants were randomized at 26 weeks to extended CBT (E-CBT) to week 48 and half to non-extended CBT (no additional CBT sessions). Measurements: The primary outcome was expired CO-confirmed, 7-day point-prevalence (PP) at 52- and 104-week follow-up. Analyses were based on intention-to-treat. Findings: PP abstinence rates at the 52-week follow-up were comparable across non-extended CBT (40{\%}) and E-CBT (39{\%}) groups [odds ratio (OR) = 0.99; 95{\%} confidence interval (CI) = 0.55, 1.78]. A similar pattern was observed across non-extended CBT (39{\%}) and E-CBT (33{\%}) groups at the 104-week follow-up (OR = 0.79; 95{\%} CI= 0.44, 1.40). Conclusion: Prolonging cognitive–behavioral therapy from 26 to 48 weeks does not appear to improve long-term abstinence from smoking.",
keywords = "Abstinence, adaptive treatment, bupropion SR, clinical trial, cognitive behavioral therapy, extended treatment, nicotine dependence, nicotine replacement therapy smoking cessation, smoking cessation, varenicline",
author = "Laude, {Jennifer R.} and Steffani Bailey and Erin Crew and Ann Varady and Anna Lembke and Danielle McFall and Anna Jeon and Diana Killen and Killen, {Joel D.} and David, {Sean P.}",
year = "2017",
month = "8",
day = "1",
doi = "10.1111/add.13806",
language = "English (US)",
volume = "112",
pages = "1451--1459",
journal = "Addiction",
issn = "0965-2140",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Extended treatment for cigarette smoking cessation

T2 - a randomized control trial

AU - Laude, Jennifer R.

AU - Bailey, Steffani

AU - Crew, Erin

AU - Varady, Ann

AU - Lembke, Anna

AU - McFall, Danielle

AU - Jeon, Anna

AU - Killen, Diana

AU - Killen, Joel D.

AU - David, Sean P.

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Aim: To test the potential benefit of extending cognitive–behavioral therapy (CBT) relative to not extending CBT on long-term abstinence from smoking. Design: Two-group parallel randomized controlled trial. Patients were randomized to receive non-extended CBT (n = 111) or extended CBT (n = 112) following a 26-week open-label treatment. Setting: Community clinic in the United States. Participants: A total of 219 smokers (mean age: 43 years; mean cigarettes/day: 18). Intervention: All participants received 10 weeks of combined CBT + bupropion sustained release (bupropion SR) + nicotine patch and were continued on CBT and either no medications if abstinent, continued bupropion + nicotine replacement therapy (NRT) if increased craving or depression scores, or varenicline if still smoking at 10 weeks. Half the participants were randomized at 26 weeks to extended CBT (E-CBT) to week 48 and half to non-extended CBT (no additional CBT sessions). Measurements: The primary outcome was expired CO-confirmed, 7-day point-prevalence (PP) at 52- and 104-week follow-up. Analyses were based on intention-to-treat. Findings: PP abstinence rates at the 52-week follow-up were comparable across non-extended CBT (40%) and E-CBT (39%) groups [odds ratio (OR) = 0.99; 95% confidence interval (CI) = 0.55, 1.78]. A similar pattern was observed across non-extended CBT (39%) and E-CBT (33%) groups at the 104-week follow-up (OR = 0.79; 95% CI= 0.44, 1.40). Conclusion: Prolonging cognitive–behavioral therapy from 26 to 48 weeks does not appear to improve long-term abstinence from smoking.

AB - Aim: To test the potential benefit of extending cognitive–behavioral therapy (CBT) relative to not extending CBT on long-term abstinence from smoking. Design: Two-group parallel randomized controlled trial. Patients were randomized to receive non-extended CBT (n = 111) or extended CBT (n = 112) following a 26-week open-label treatment. Setting: Community clinic in the United States. Participants: A total of 219 smokers (mean age: 43 years; mean cigarettes/day: 18). Intervention: All participants received 10 weeks of combined CBT + bupropion sustained release (bupropion SR) + nicotine patch and were continued on CBT and either no medications if abstinent, continued bupropion + nicotine replacement therapy (NRT) if increased craving or depression scores, or varenicline if still smoking at 10 weeks. Half the participants were randomized at 26 weeks to extended CBT (E-CBT) to week 48 and half to non-extended CBT (no additional CBT sessions). Measurements: The primary outcome was expired CO-confirmed, 7-day point-prevalence (PP) at 52- and 104-week follow-up. Analyses were based on intention-to-treat. Findings: PP abstinence rates at the 52-week follow-up were comparable across non-extended CBT (40%) and E-CBT (39%) groups [odds ratio (OR) = 0.99; 95% confidence interval (CI) = 0.55, 1.78]. A similar pattern was observed across non-extended CBT (39%) and E-CBT (33%) groups at the 104-week follow-up (OR = 0.79; 95% CI= 0.44, 1.40). Conclusion: Prolonging cognitive–behavioral therapy from 26 to 48 weeks does not appear to improve long-term abstinence from smoking.

KW - Abstinence

KW - adaptive treatment

KW - bupropion SR

KW - clinical trial

KW - cognitive behavioral therapy

KW - extended treatment

KW - nicotine dependence

KW - nicotine replacement therapy smoking cessation

KW - smoking cessation

KW - varenicline

UR - http://www.scopus.com/inward/record.url?scp=85018744384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018744384&partnerID=8YFLogxK

U2 - 10.1111/add.13806

DO - 10.1111/add.13806

M3 - Article

C2 - 28239942

AN - SCOPUS:85018744384

VL - 112

SP - 1451

EP - 1459

JO - Addiction

JF - Addiction

SN - 0965-2140

IS - 8

ER -